The Potential Targets and Mechanisms of a Carbazole and Pyrazole Containing Anticancer Compound

Author(s): Jingping Xie*, John C. Gore

Journal Name: Current Cancer Drug Targets

Volume 20 , Issue 5 , 2020

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Aims: Characterization of a small anticancer compound.

Background: The development of small molecules as new anti-cancer therapeutics is necessary to improve anti-tumor efficacy and reduce toxicities, especially for the treatment of brain tumors, where only small molecules can effectively cross the brain-blood barrier. Several novel hits were previously selected by concurrently screening colon and glioma cancer cell lines with a sensorconjugated reporter system. Here, we focused on one of them.

Objective: Elucidating the potential target(s) of a novel anticancer compound.

Methods: Computer-assisted structural and motif analysis (least absolute shrinkage and selection operator or LASSO score) was used to assess compound’s targets, then direct kinase activity assays were used for the confirmation; Western blot of phosphorylated kinases, as well as FACS and caspase 3/7 activity assays, were used to decipher the action mechanisms. Finally, the expression profiling of proteins involved in various G-protein pathways by real-time PCR was performed.

Results: The small chemical, (4E)-4-[2-(9-ethyl-9H-carbazol-3-yl)hydrazin-1-ylidene]-3-methyl- 4,5-dihydro-1H-pyrazol-5-one, with a formula C18H17N5O and MW of 319.36, designated as VUGX01, was predicted to be a ligand/inhibitor to receptor tyrosine kinases (RTKs) by computer analysis (least absolute shrinkage and selection operator or LASSO score). However, direct analysis with recombinant kinases showed that it is not an effective inhibitor to the popular receptor kinases at 1μM concentration. This compound can activate caspases in some tumor cell lines but has minimal effects on the cell cycle. Drug treatments lead to the changes in phosphorylation of AKT and c- RAF, as well as the expression level of MAP2K, suggesting this compound may interact with Gprotein coupled receptors (GPCRs). The expression profiling of 82 proteins involved in various Gprotein pathways by real-time PCR showed that the treatment up-regulates the expression of several proteins, including angiotensinogen, angiotensin II receptor, and IP3-kinase catalytic subunit gamma.

Conclusion: VUGX01 can effectively block proliferation and induce apoptosis of certain types of cancer cells, even it is predicted by high LASSO score, but it is not an effective RTKs inhibitor, it may inhibit cell growth through acting as a novel ligand to one or several GPCRs.

Keywords: Apoptosis, HTS, drug target, caspase, GPCRs, colorectal cancer, glioma.

[1]
(a) Rask-Andersen, M.; Almén, M.S.; Schiöth, H.B. Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov., 2011, 10(8), 579-590.
[http://dx.doi.org/10.1038/nrd3478] [PMID: 21804595]
(b) Swinney, D.C.; Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov., 2011, 10(7), 507-519.
[http://dx.doi.org/10.1038/nrd3480] [PMID: 21701501]
[2]
(a) Zheng, W.; Thorne, N.; McKew, J.C. Phenotypic screens as a renewed approach for drug discovery. Drug Discov. Today, 2013, 18(21-22), 1067-1073.
[http://dx.doi.org/10.1016/j.drudis.2013.07.001] [PMID: 23850704]
(b) Sams-Dodd, F. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov. Today, 2013, 18(5-6), 211-217.
[http://dx.doi.org/10.1016/j.drudis.2012.10.010] [PMID: 23131208]
(c) Williams, M. Productivity shortfalls in drug discovery: contributions from the preclinical sciences? J. Pharmacol. Exp. Ther., 2011, 336(1), 3-8.
[http://dx.doi.org/10.1124/jpet.110.171751] [PMID: 20739456]
[3]
Vogt, A.; Lazo, J.S. Chemical complementation: A definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets. Pharmacol. Ther., 2005, 107(2), 212-221.
[http://dx.doi.org/10.1016/j.pharmthera.2005.03.002] [PMID: 15925410]
[4]
Reaume, A.G. Drug repurposing through nonhypothesis driven phenotypic screening. Drug Discov. Today, 2011, 8(3), 4.
[5]
Xie, J.; Wang, C.; Virostko, J.; Manning, H.C.; Pham, W.; Bauer, J.; Gore, J.C. A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs. ChemBioChem, 2013, 14(12), 1494-1503.
[http://dx.doi.org/10.1002/cbic.201300142] [PMID: 23881799]
[6]
Xie, J.; Wang, C.; Gore, J.C. High throughput screening for colorectal cancer specific compounds. Comb. Chem. High Throughput Screen., 2016, 19(3), 180-188.
[http://dx.doi.org/10.2174/1386207319666160202120928] [PMID: 26830359]
[7]
Zalewska, M.; Siara, M.; Sajewicz, W. G protein-coupled receptors: abnormalities in signal transmission, disease states and pharmacotherapy. Acta Pol. Pharm., 2014, 71(2), 229-243.
[PMID: 25272642]
[8]
Liu, Y.; An, S.; Ward, R.; Yang, Y.; Guo, X-X.; Li, W.; Xu, T-R. G protein-coupled receptors as promising cancer targets. Cancer Lett., 2016, 376(2), 226-239.
[http://dx.doi.org/10.1016/j.canlet.2016.03.031] [PMID: 27000991]
[9]
Issa, S.; Prandina, A.; Bedel, N.; Rongved, P.; Yous, S.; Le Borgne, M.; Bouaziz, Z. Carbazole scaffolds in cancer therapy: A review from 2012 to 2018. J. Enzyme Inhib. Med. Chem., 2019, 34(1), 1321-1346.
[http://dx.doi.org/10.1080/14756366.2019.1640692] [PMID: 31328585]
[10]
Sanchez-Martinez, C.; Shih, C.; Faul, M.M.; Zhu, G.; Paal, M.; Somoza, C.; Li, T.; Kumrich, C.A.; Winneroski, L.L.; Xun, Z.; Brooks, H.B.; Patel, B.K.R.; Schultz, R.M.; DeHahn, T.B.; Spencer, C.D.; Watkins, S.A.; Considine, E.; Dempsey, J.A.; Ogg, C.A.; Campbell, R.M.; Anderson, B.A.; Wagner, J. Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors. Bioorg. Med. Chem. Lett., 2003, 13(21), 3835-3839.
[http://dx.doi.org/10.1016/S0960-894X(03)00791-1] [PMID: 14552791]
[11]
Naim, M.J.; Alam, O.; Nawaz, F.; Alam, M.J.; Alam, P. Current status of pyrazole and its biological activities. J. Pharm. Bioallied Sci., 2016, 8(1), 2-17.
[http://dx.doi.org/10.4103/0975-7406.171694] [PMID: 26957862]
[12]
Reid, D.; Sadjad, B.S.; Zsoldos, Z.; Simon, A. LASSO-ligand activity by surface similarity order: a new tool for ligand based virtual screening. J. Comput. Aided Mol. Des., 2008, 22(6-7), 479-487.
[http://dx.doi.org/10.1007/s10822-007-9164-5] [PMID: 18204980]
[13]
Manning, H.C.; Merchant, N.B.; Foutch, A.C.; Virostko, J.M.; Wyatt, S.K.; Shah, C.; McKinley, E.T.; Xie, J.; Mutic, N.J.; Washington, M.K.; LaFleur, B.; Tantawy, M.N.; Peterson, T.E.; Ansari, M.S.; Baldwin, R.M.; Rothenberg, M.L.; Bornhop, D.J.; Gore, J.C.; Coffey, R.J. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin. Cancer Res., 2008, 14(22), 7413-7422.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0239] [PMID: 19010858]
[14]
Altomare, D.A.; Testa, J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene, 2005, 24(50), 7455-7464.
[http://dx.doi.org/10.1038/sj.onc.1209085] [PMID: 16288292]
[15]
Jacinto, E.; Facchinetti, V.; Liu, D.; Soto, N.; Wei, S.; Jung, S.Y.; Huang, Q.; Qin, J.; Su, B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell, 2006, 127(1), 125-137.
[http://dx.doi.org/10.1016/j.cell.2006.08.033] [PMID: 16962653]
[16]
Lappano, R.; Maggiolini, M. G protein-coupled receptors: Novel targets for drug discovery in cancer. Nat. Rev. Drug Discov., 2011, 10(1), 47-60.
[http://dx.doi.org/10.1038/nrd3320] [PMID: 21193867]
[17]
Filardo, E.J.; Quinn, J.A.; Bland, K.I.; Frackelton, A.R., Jr Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol., 2000, 14(10), 1649-1660.
[http://dx.doi.org/10.1210/mend.14.10.0532] [PMID: 11043579]
[18]
Hart, S.; Fischer, O.M.; Prenzel, N.; Zwick-Wallasch, E.; Schneider, M.; Hennighausen, L.; Ullrich, A. GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol. Chem., 2005, 386(9), 845-855.
[http://dx.doi.org/10.1515/BC.2005.099] [PMID: 16164409]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 5
Year: 2020
Published on: 05 June, 2020
Page: [364 - 371]
Pages: 8
DOI: 10.2174/1568009620666200115162343
Price: $65

Article Metrics

PDF: 11
HTML: 2